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Abstract
Background. Kidney Disease Outcomes Quality
Initiative (KDOQI) chronic kidney disease (CKD)
guidelines have focused on the utility of using the
modified four-variable MDRD equation (now trace-
able by isotope dilution mass spectrometry IDMS) in
calculating estimated glomerular filtration rates
(eGFRs). This study assesses the practical implications
of eGFR correction equations on the range of
creatinine assays currently used in the UK and further
investigates the effect of these equations on the
calculated prevalence of CKD in one UK region
Methods. Using simulation, a range of creatinine data
(30–300 mmol/l) was generated for male and female
patients aged 20–100 years. The maximum differences
between the IDMS and MDRD equations for all 14
UK laboratory techniques for serum creatinine mea-
surement were explored with an average of individual
eGFRs calculated according to MDRD and IDMS
<60 ml/min/1.73m2 and 30 ml/min/1.73m2. Similar
procedures were applied to 712 540 samples from
patients 18 years (reflecting the five methods for
serum creatinine measurement utilized in Northern
Ireland) to explore, graphically, maximum differences
in assays. CKD prevalence using both estimation
equations was compared using an existing cohort of
observed data.
Results. Simulated data indicates that the majority of
laboratories in the UK have small differences between
the IDMS and MDRD methods of eGFR measure-
ment for stages 4 and 5 CKD (where the averaged
maximum difference for all laboratory methods was
1.27ml/min/1.73m2 for females and 1.59ml/min/
1.73m2 for males). MDRD deviated furthest
from the IDMS results for the Endpoint Jaffe
method: the maximum difference of 9.93ml/min/
1.73m2 for females and 5.42ml/min/1.73m2 for males
occurred at extreme ages and in those with eGFR
>30ml/min/1.73m2. Observed data for 93,870 patients
yielded a first MDRD eGFR <60ml/min/1.73m2 in
2001. 66 429 (71%) had a second test >3 months later
of which 47 093 (71%) continued to have an eGFR
<60 ml/min/1.73m2. Estimated crude prevalence was
3.97% for laboratory detected CKD in adults using the
MDRD equation which fell to 3.69% when applying
the IDMS equation. Over 95% of this difference in
prevalence was explained by older females with stage 3
CKD (eGFR 30–59ml/min/1.73m2) close to the stage
2 CKD (eGFR 60–90ml/min/1.73m2) interface.
Conclusions. Improved accuracy of eGFR is obtainable
by using IDMS correction especially in the earlier stages
of CKD 1–3. Our data indicates that this improved
accuracy could lead to reduced prevalence estimates and
potentially a decreased likelihood of onward referral to
nephrology services particularly in older females.
Keywords: CKD; creatinine standardization; eGFR;
IDMS; MDRD; prevalence
Introduction
Recent guidelines [1] for assessment of renal function
have focused on the utility and benefit of using the
modified 4-variable MDRD equation [2] (traceable by
isotope dilution mass spectrometry, IDMS), first
described by Levey et al. [3] in 2005. The traceable
IDMS method was introduced following recalibration
of Beckman Synchron CX3 (Global Medical
Instrumentation, Inc., Ramsey, Minnesota) assay to
the Roche/Hitachi P module Creatinase Plus enzy-
matic assay (Roche Diagnostics, Basel, Switzerland),
traceable to an IDMS assay at the National Institute
of Standards and Technology (NIST). This traceable
eGFR estimation equation, provided by Levey and
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coworkers, has become the ‘gold standard’ by which
all other eGFR estimation equations are measured and
is part of a global attempt to standardize creatinine
assays to allow accurate and reproducible eGFR
reporting [4]. The impact of eGFR standardization is
such that recent publications have explicitly referred to
its use in their methods implying that in studies of
chronic kidney disease (CKD), failure to standardize
eGFR in this way may reduce the validity of the study
[5].
The original 4-variable MDRD equation and its
subsequent use in simplifying CKD guidelines have
been called into question because of concern surround-
ing the standardization of eGFR. The recent change to
reporting ‘standardized eGFR’ has generated doubt
about the validity of CKD epidemiology studies that
were based on previously calculated eGFRs [6,7].
Practising nephrologists are also concerned that the
original 4-variable MDRD may have led to misclassi-
fication of CKD stage in patients with renal disease,
potentially influencing the likelihood of referral to
secondary care.
Our study assesses the immediate practical impact of
introducing the traceable IDMS method of eGFR
calculation (facilitated by nationally provided appro-
priate intermediary corrections) compared to the
original MDRD equation on reported prevalence of
CKD. We also compared these two eGFR calculations
using a mathematical software package, MATLAB.
Methods
Data were received on all serum creatinine assays performed
in Northern Ireland laboratories between 1 January 2001 and
31 December 2002. Northern Ireland is a single predomi-
nantly rural region of the United Kingdom with a stable
population of almost 1.7 million, 99% of whom are of white
Caucasian origin. Individual blood sample records were
linked to produce a patient database as described previously
[8]. We were able to match 99.7% of the test results to
individual patient’s database. This initial cohort was assessed
in two separate analyses. In the first, a database of unique
patients with samples tested in 2001 was identified to allow
the calculation of prevalence of CKD as defined by Kidney
Disease Outcomes Quality Initiative (KDOQI):
GFR< 60ml/min/1.73m2 for 3 months, with or without
kidney damage [1].
In accordance with this statement, all patients aged
20 years and over were selected if they had one eGFR
measurement <60ml/min/1.73m2 in 2001, followed by
a second measurement <60ml/min/1.73m2 at an interval of
3 calendar months. Estimated GFR was calculated using
the MDRD and subsequently recalculated using the IDMS
correction equation. The five creatinine assays used in
Northern Ireland at that time are identified in the shaded
area in Table 1. In 2001–2002 no formal regional creatinine
standardization took place in Northern Ireland; laboratories
throughout the UK were dependent on assay manufacturer’s
quality control systems to ensure comparability.
Estimated GFR measurements were categorized according
to KDOQI stages 3, 4 and 5, using the value recorded for the
first test where eGFR was <60ml/min/1.73m2 for each
patient between 1 January 2001 and 31 December 2001. The
patient’s age at the time of the first test was used to
assign patients to an age band. The prevalence of CKD in
Northern Ireland was calculated based on the denominator
population (by 10-year age bands) available from the
population census in April 2001 [9]. The total population
was enumerated as 1 685 268, with 1 185 114 aged 20 years
and over. Repeat calculation of prevalence was performed
using the IDMS correction.
Table 1. Intercepts and slopes including maximum deviations for all 14UK laboratory methods of serum creatinine measurement
Maximum deviation between MDRD and IDMS eGFR
for creatinine assay
Method
ID
Laboratory method Intercept Slopea Maximum deviation (F) Maximum deviation (M)
<60 eGFR <30 eGFR <60 eGFR <30 eGFR
1 Roche Modular reagents [11BO] 3.08 1.004 1.37 1.13 1.81 1.26
2 Beckman reagents [11BK] 5.92 0.994 1.14 0.96 1.29 1.20
3 Abbott reagents [11AB] 13.21 0.940 4.01 1.50 2.09 2.06
4 Dry Slide, OCD (J&J) slides [1JJ] 7.71 0.988 2.32 0.87 1.17 1.16
5 Olympus, O’Leary 24.55 0.854 8.57 2.66 3.58 3.57
6 Bayer reagents [11TE] 17.78 0.927 7.25 1.40 3.60 1.88
7 Dade Behring reagents [11BE] 6.78 1.030 4.25 0.80 2.92 0.44
8 Olympus reagents [11OL] 16.14 0.955 7.60 0.90 4.34 1.21
9 Roche Integra reagents [11RO] 2.03 0.988 0.96 1.13 1.81 1.26
10 ILab reagents [6IL] 21.77 0.908 9.58 1.51 5.11 2.03
11 Enzymatic 0.26 1.011 3.13 1.51 3.07 1.50
12 Endpoint Jaffe 22.02 0.910 9.93 1.44 5.42 1.94
13 Kinetic Jaffe 11.60 0.970 4.56 0.92 2.22 1.24
14 All methodsb 12.73 0.959 4.84 1.08 2.25 1.46
Averaged maximum deviation for all 14 methods: 4.97 1.27 2.91 1.59
Notes: Methods 1–5 (shaded) represent the laboratory techniques used in Northern Ireland.
aIntercept and slope provided by UKNEQAS12.
b‘All methods’ refers to substitute intercept and slope (recommended by NEQAS) to be used if laboratory method is unknown.
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MATLAB is a high-level technical computing language
and interactive environment for algorithm development,
data visualization, data analysis and numeric computation
[10–12]. In our second analysis, a unique code was written
in MATLAB to generate data to explore the maximum
differences possible between the MDRD and the IDMS
traceable equations for stages 3–5 CKD. That is, the well-
established MDRD and IDMS equations were used as input
and forced to loop over a range of serum creatinine values
between 30 and 300 mmol/l with a range of simulated patients
aged 20–100 years. The maximum difference between the
averaged MDRD and the averaged IDMS output was
constrained, whereby the average had to be <60ml/min/
1.73m2 and <30ml/min/1.73m2, in turn. All 14 laboratory
methods used in the UK were explored using the intercepts
and slopes for the IDMS equation provided by United
Kingdom National External Quality Assessment Service
(UKNEQAS) [13].
This concept was further explored in the directly observed
Northern Ireland data collected between 1 January 2001 and
31 December 2002. Whilst KDOQI requirements for
prevalence calculation stipulated an age criteria 20 years,
The Renal Association UK guidelines [14] released in 2006
advised eGFR calculation for all individuals aged 18 years.
Therefore in our second analysis, we selected observed results
from any individual 18 years to compare the MDRD
estimate to the IDMS correction. The agreement between the
two equations was then explored by plotting the difference
against the average for all samples. The plotted graph was
then colour coded by laboratory method to highlight the
maximum deviation for each method that permits compar-
ison of the observed and simulated data in Table 1 and
Figure 2.
Results
Table 1 displays the intercepts and slopes used in the
IDMS traceable equations for all 14 UK serum
creatinine assays, provided by NEQAS. Further, it
highlights the maximum deviation for all the 14
methods when the average between the IDMS and
the MDRD was <60ml/min/1.73m2 and <30ml/min/
1.73m2 for both females and males over all ages and
serum creatinines as defined in the methods section.
Only small differences are seen comparing the IDMS
with the MDRD methods of eGFR calculation in
patients with stage 4 or 5 CKD where the averaged
maximum difference for all laboratory methods was
1.27ml/min/1.73m2 for females and 1.59ml/min/
1.73m2 for males. Analysing all UK methods, the
maximum deviation between the IDMS and the
MDRD methods occurred with the Endpoint Jaffe
method with a value of 9.93ml/min/1.73m2 for females
and 5.42ml/min/1.73m2 for males. However, these
maximums occurred at extremes of age and in those
with eGFR reflecting stage 3 CKD. Figure 1 illustrates
graphically an example of the variation that exists
between the MDRD and the IDMS traceable equa-
tions for all 14 UK laboratory techniques, across
serum creatinine values for females aged 70.
Below 60ml/min/1.73m2 (the dashed line), the
difference between all methods of serum creatinine
measurement diminishes as renal function declines.
Figure 2 illustrates observed data from the Northern
Ireland population and represents the plot of 712 540
samples for patients 18 years or older who had an
average eGFR< 60ml/min/1.73m2. The maximum
deviation between the IDMS and the MDRD equa-
tions is just over 8.5ml/min/1.73m2, which occurred
using method 5 Olympus O’Leary (yellow plot)
consistent with the simulated data. For estimated
GFRs of >60ml/min/1.73m2, the graph shows greater
dispersion, that is, larger differences between the two
equations.
Prevalence was calculated using blood samples
tested for serum creatinine in Northern Ireland
laboratories between 1 January 2001 and 31
December 2001. After matching and merging sample
data, a patient database was generated containing
345 160 patients aged 20 years and over who had one
or more serum creatinine tests performed in 2001 and
sufficient additional information (age and gender)
to calculate eGFR. We then applied the definition
of CKD based on a first eGFR< 60ml/min/1.73m2
followed by a second eGFR< 60ml/min/1.73m2 at an
interval of 3 calendar months. This yielded 93 870
patients with a first eGFR< 60ml/min/1.73m2
between 1 January 2001 and 31 December 2001. Out
of those, 71% (66 429) went on to have a second test
3 months later. Of these, 71% (47 093) had a
subsequent test which was still <60ml/min/1.73m2,
thus meeting the definition of CKD based on eGFR as
outlined by KDOQI [1]. The population of Northern
Ireland aged 20 years and over was 1 185 114 at the
census in 2001. The crude prevalence rate of laboratory
detected CKD in Northern Ireland in adults aged
20 years and over is therefore 3.97%. Using the
IDMS correction, the overall calculated prevalence
was reduced to 3.69%. Over 95% of the difference in
prevalence was explained by older females, previously
classified as having stage 3 CKD (eGFR 30–59ml/min/
1.73m2) based on the MDRD equation being reclassi-
fied into stage 2 CKD (eGFR 60–90ml/min/1.73m2)
when the IDMS calculation was applied. The MDRD
and IDMS results were categorized by CKD stage,
gender and age (Table 2). The proportion of patients in
CKD stages 3, 4 and 5 differed significantly between
the MDRD-derived classification and the IDMS
classification (p< 0.001, 2 629). The main contribu-
tors to the chi-square test statistic were older females,
clustered close to the upper limit of stage 3 CKD
(eGFR 30–59ml/min/1.73m2). These results are illus-
trated in Table 2 with the results accounting for the
change in prevalence in the shaded area.
Discussion
This study demonstrates that there is little difference
between eGFR values calculated by the MDRD and
IDMS traceable equations for individual patients with
stage 4 CKD (eGFR 15–29ml/min/1.73m2) or stage
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All above units represent absolute changes in eGFR (ml/min/1.73 m2)
Blue: Method 1, Roche Modular
Red: Method 2, Beckman 
Pink: Method 3, Abbott 
Green: Method 4, OCD 
Yellow: Method 5, Olympus
(ml/min/1.73m2)
Fig. 2. Maximum deviations between MDRD and IDMS eGFR equations in Northern Ireland observed data.
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Fig. 1. Variation between MDRD and IDMS traceable equations for all 14 laboratory methods of serum creatinine measurement in a
simulated female patient aged 70.
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5 CKD (eGFR< 15ml/min/1.73m2). However on
a population level, the difference between these two
eGFR equations does make a significant difference to
the overall prevalence. This is because some patients,
particularly older females, are reclassified from stage
3 CKD (eGFR 30–59ml/min/1.73m2) by the MDRD
equation to stage 2 CKD (eGFR 60–90ml/min/
1.73m2), using the IDMS traceable method of eGFR
calculation. This difference in eGFR classification
impacts on the overall prevalence rate attributed to
CKD stages 3, 4 and 5 and will have implications for
CKD epidemiological research and public health
policy.
Clinical pragmatism is crucial in the management of
CKD; and in the absence of evidence-based guidelines
expert consensus opinion is often the default position.
Sensible referral criteria and management guidelines
have to be designed to maximize benefit to the greatest
number of patients possible. The introduction of
eGFR reporting was, in part, a response to numerous
epidemiological studies that confirmed a higher pre-
valence of early CKD and its associated cardiovascular
mortality than had previously been appreciated [15,16].
In practice, the introduction of eGFR has improved
awareness of CKD beyond the nephrology community.
It is hoped that future use will help reduce the
likelihood of late referral, particularly evident in the
older population.
Nephrologists have extensively debated the defini-
tion of CKD, and even now there is a little consensus
over the clinical significance of having an eGFR
between 60ml/min/1.73m2 and 90ml/min/1.73m2
[17]. It was already known that eGFR calculation,
using the MDRD equation, differed from gold
standard methods of GFR estimations, especially
when eGFR is >60ml/min/1.73m2 [18,19]. The
original MDRD equation was validated in patients
with a mean GFR of 39.8 (21.2)ml/min/1.73m2,
aged 50.6 (12.7) years with a mean serum creatinine
of 203 (106)mmol/l rather than in patients with much
better renal function. Within this group of patients
with milder impairment of kidney function, additional
information about other clinical variables such as
proteinuria and hypertension is required to help
determine individual risk for progression of CKD [20].
Considering the accepted inadequacies of eGFR in
patients with better renal function (CKD stages 1
and 2), we chose to concentrate our analysis on those
with CKD stages 3, 4 and 5. Using statistical models
and a large population cohort, we have shown that
standardization with ‘gold standard’ IDMS calculation
has a smaller effect on estimation of eGFR in
these categories. Current UK guidelines designate
CKD as a patient with an eGFR <60ml/min/1.73m2
(stage 3, 4 and 5 CKD). Considering the potentially
large clinical burden of CKD within health care
systems, current attempts to increase accuracy in
eGFR reporting are to be welcomed, especially if
they result in decreased clinical demand on renal
services. The IDMS correction is a minor, but none the
less significant, advance in accuracy; it has minimal
effect on estimation in patients with an eGFR <45mls/
min/1.73m2, but we have demonstrated its improved
accuracy in those middle aged to elderly females with
an eGFR slightly above 60mls/min/1.73m2. This is
particularly important considering the recent guide-
lines to define stage 3 CKD as an eGFR <60mls/min/
1.73m2.
Standardization with the IDMS correction is also
important [3,5,21,22] for epidemiological and long-
itudinal studies in that it offers the most accurate
estimation of eGFR practically available. However, we
Table 2. Effect of IDMS correction on prevalence of CKD in observed Northern Ireland data tabulated by 10-year age bands
Numbers of patients categorized by age and MDRD eGFR CKD stage (IDMS correction effect)
3 4 5 TOTAL
Age M F M F M F M F
20–29 55 (5)a 49 (0) 7 (5) 15 (1) 24 (0) 15 (3) 86 (10) 79 (2)
[0.42] [0.00] [2.08] [0.07] [0.00] [0.50]
30–39 129 (2) 173 (7) 31 (3) 23 (1) 38 (2) 29 (0) 198 (7) 225 (6)
[0.03] [0.30] [0.26] [0.04] [0.10] [0.00]
40–49 289 (21) 538 (56) 56 (5) 50 (3) 51 (2) 39 (0) 396 (28) 627 (53)
[1.42] [6.51] [0.41] [0.17] [0.08] [0.00]
50–59 1054 (49) 2244 (342) 89 (16) 93 (6) 89 (4) 56 (3) 1232 (69) 2393 (333)
[2.18] [61.50] [2.44] [0.36] [0.17] [0.15]
60–69 3136 (21) 5825 (942) 216 (15) 263 (21) 106 (15) 121 (10) 3458 (9) 6209 (911)
[0.14] [181.73] [0.97] [1.55] [1.86] [0.76]
70–79 5442 (145) 10758 (1371) 424 (64) 724 (67) 122 (18) 117 (23) 5988 (63) 11599 (1281)
[3.97] [200.24] [8.39] [5.68] [2.31] [3.78]
80þ 3673 (124) 9282 (940) 380 (84) 1077 (108) 81 (7) 110 (17) 4134 (33) 10469 (815)
[4.33] [105.92] [15.21] [9.84] [0.56] [2.28]
Totals 13778 (213) 28869 (3658) 1203 (192) 2245 (205) 511 (48) 487 (56) 15492 (27) 31601 (3397)
42647 (3871) 3448 (397) 998 (104) 47093 (3370)
aBy way of example: 55 male subjects (20–29) were originally categorized as stage 3 CKD using MDRD equation. (5) Additional male subjects
were recategorized to stage 3 using IDMS correction; the contribution to overall 2 was [0.42].
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would suggest that more emphasis needs to be placed
on the rate of eGFR decline and associated risk factors
for rapid progression (proteinuria and hypertension)
[23] that are more relevant to poor outcomes in
CKD. The standardization of eGFR measurement
may modestly improve individual measurement of
eGFR >60ml/min/1.73m2, but only serial measure-
ments, with direct comparison, can provide us with
accurate information on progression of CKD.
The inherent weakness of the MDRD equation (and
IDMS modification) is that they are, by definition,
estimates derived from a highly selected population
recruited for a clinical trial of CKD progression.
The clinical application of eGFR must be tempered
by knowledge and understanding their limitations.
The most obvious limiting factor to the accuracy of
eGFR estimation is the potential variance in initial
creatinine estimation [24,25]. This study clearly demon-
strates the problems associated with inter-assay
variance and its subsequent effect on eGFR estimation.
Current attempts to achieve consensus will hopefully
result in assay manufacturers producing internation-
ally standardized methods of creatinine estimation.
In the interim, national bodies such as UKNEQAS
have facilitated the immediate introduction of the
IDMS equation by providing correction factors for
current creatinine assays [13].
The IDMS equation was devised only for the use
with traceable creatinine assays [3]; however, consider-
ing the delay in achieving global standardization in
assays, it is important to understand and investigate
the practical benefits of using this correction equation
in preference to the standard 4-variable MDRD
equation in the interim period. Whilst this methodol-
ogy is imperfect, it represents current practice and this
study attempts to assess both the strengths and the
weaknesses of its practical implementation.
Standardized eGFR measurements are important
for determining an individual patient’s rate of CKD
progression and providing more accurate assessment of
population prevalence of CKD. Nevertheless eGFR is
not an accurate measurement of current clinical state;
it does not take into account blood pressure, pro-
teinuria, and presence of diabetes or renal failure
symptoms. Renal risk scores and the use of alternative
markers such as cystatin C may eventually supplement
the current estimation techniques; but until that time,
recurrent assessment in risk groups is the only
practically applicable method [26].
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